Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock in the Biotechnology Industry, returning 13,702.4%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 13,702.4% |
Abivax SA American Depositary Shares (ABVX) | 1,151.52% |
Nanobiotix (NBTX) | 861.74% |
Protagenic Therapeutics (PTIXW) | 669.23% |
Palvella Therapeutics (PVLA) | 503.7% |
I-Mab (IMAB) | 470.59% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 462.55% |
ABVC BioPharma (ABVC) | 457.63% |
Ainos (AIMDW) | 447.67% |
Lixte Biotechnology (LIXTW) | 428.57% |
Neuphoria Therapeutics (NEUP) | 420.55% |
DBV Technologies (DBVT) | 382.37% |
Monopar Therapeutics (MNPR) | 358.91% |
Cidara Therapeutics (CDTX) | 308.56% |
Quantum BioPharma (QNTM) | 302.89% |
Invivyd (IVVD) | 302.13% |
GRAIL, LLC (GRAL) | 299.16% |
ATAI Life Sciences (ATAI) | 297.81% |
Celcuity LLC (CELC) | 274.21% |
Matinas BioPharma (MTNB) | 270.52% |
Galectin Therapeutics (GALT) | 262.6% |
Uniqure (QURE) | 256.58% |
CervoMed (CRVO) | 255.83% |
Lineage Cell Therapeutics (LCTX) | 242.6% |
CytomX Therapeutics (CTMX) | 241.58% |
